Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Online First
    • Multimedia
    • Collections
    • Past Issues
    • Articles by Subject
    • Articles by Type
    • Supplements
    • The Issue in Brief (Plain Language Summaries)
    • Call for Papers
  • Info for
    • Authors
    • Reviewers
    • Media
    • Job Seekers
  • About
    • Annals of Family Medicine
    • Editorial Staff & Boards
    • Sponsoring Organizations
    • Copyrights & Permissions
    • Announcements
  • Engage
    • Engage
    • e-Letters (Comments)
    • Subscribe
    • RSS
    • Email Alerts
    • Journal Club
  • Contact
    • Feedback
    • Contact Us
  • Careers

User menu

  • My alerts

Search

  • Advanced search
Annals of Family Medicine
  • My alerts
Annals of Family Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Online First
    • Multimedia
    • Collections
    • Past Issues
    • Articles by Subject
    • Articles by Type
    • Supplements
    • The Issue in Brief (Plain Language Summaries)
    • Call for Papers
  • Info for
    • Authors
    • Reviewers
    • Media
    • Job Seekers
  • About
    • Annals of Family Medicine
    • Editorial Staff & Boards
    • Sponsoring Organizations
    • Copyrights & Permissions
    • Announcements
  • Engage
    • Engage
    • e-Letters (Comments)
    • Subscribe
    • RSS
    • Email Alerts
    • Journal Club
  • Contact
    • Feedback
    • Contact Us
  • Careers
  • Follow annalsfm on Twitter
  • Visit annalsfm on Facebook
EditorialEditorials

Returning to a Patient-Centered Approach in the Management of Hypothyroidism

Jill Schneiderhan and Suzanna Zick
The Annals of Family Medicine September 2020, 18 (5) 388-389; DOI: https://doi.org/10.1370/afm.2602
Jill Schneiderhan
University of Michigan Medical School, Ann Arbor, Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jillsch@med.umich.edu
Suzanna Zick
University of Michigan Medical School, Ann Arbor, Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading
Key words
  • hypothyroidism
  • primary health care
  • shared decision making

Shared decision making is an important aspect of high-quality health care and incorporates understanding patients’ beliefs around how medication works, the potential side effects, and expected benefits. Gaining this understanding helps to guide the decision of which medications most closely align with patients’ beliefs and expectations. This may be especially important for improving adherence to chronic medications, and in particular, for thyroid medication where 40 to 50% of patients do not take their medication as prescribed.1

The historical context sheds light on this topic by highlighting the shift from patient-centered symptom management to one based on laboratory values, which diminishes room for the patient experience. Before the 1970s, hypothyroidism was treated with desiccated thyroid products (dehydrated porcine or bovine thyroid). Desiccated thyroid products contain a combination of thyroxine (T4) and triiodothyronine (T3) in an approximately 4:1 ratio, and historically were titrated to the cessation of symptoms, while monitoring for thyrotoxicosis.2 In the 1970s a shift occurred in both the supplementation and measuring of T3 and T4, which led to better assessment of what happened with replacement of individual synthetic hormones. It was noted that replacing T3 alone led to large swings in T3 levels shortly after taking the drug which did not mimic physiologic levels seen in euthyroid individuals. When, however, synthetic T4 (levothyroxine) was introduced it resulted in T3 levels that were normalized throughout the day instead of fluctuating. Thus, the idea that peripheral tissue conversion supplied all the T3 that was needed to normalize thyroid function took hold. This was confirmed by the development of the assay for thyroid stimulating hormone (TSH), which measured stability of thyroid function over time, and remained steady with levothyroxine-only dosing. As such, the end goal for the treatment of hypothyroidism shifted from symptom control to achieving a normal TSH.3 The focus on normal TSH, and concerns over the lack of batch-to-batch consistency in desiccated thyroid products (they are standardized for iodine content) led to the use of desiccated thyroid products being actively discouraged.4

This one-size-fits-all approach for treating hypothyroidism does not work, however, for all patients. Emerging evidence shows that for many patients, symptoms persist despite normal TSH values.5 In a qualitative study, patients who continued to feel unwell with normalized TSH reported feeling that their physicians were not willing to look further into why their symptoms were persisting.6 In addition, patients often reported that the vague nature of their symptoms along with lack of control over their symptoms, leave them feeling invalidated and without answers.7 In fact, these ongoing symptoms may have a physiologic cause. New information has emerged that conversion of T4 to T3 by exogenous tissue is more complex than previously described. For instance, patients on levothyroxine alone have higher T4, lower T3,8 lower energy expenditure,9 and ongoing abnormalities of lipid metabolism8; all pointing to a lack of appropriate thyroid metabolism. Further, in thyroidectomy patients the amount of supplementation needed to achieve normalization of T3 levels is such that it leads to suppression of TSH,10,11 which may explain why some patients lack complete resolution with normal TSH and feel resolution of symptoms with suppressed TSH levels.

One possible way of addressing these imbalances and persistence of symptoms is the addition of T3, which desiccated thyroid products naturally contain. A barrier to their use, however, is the ongoing concern that TSH will not be consistently maintained within normal ranges. Kuye et al12 has contributed to our understanding of this concern in their retrospective matched cohort study in this issue. They begin a much-needed investigation into whether patients prescribed synthetic levothyroxine compared with desiccated thyroid had differences in TSH stability over the course of 3 years. Their results in 870 hypothyroid patients matched for age, sex, and ethnicity showed no difference in longitudinal TSH stability between desiccated thyroid products and synthetic levothyroxine, and despite more variation in visit-to-visit TSH levels variability in the patients taking desiccated thyroid, all patients regardless of the thyroid medication were euthyroid 79% of the time.

Further prospective studies are needed to confirm these results and to explore differences in more diverse patient populations, such as Hashimoto’s thyroiditis as well as on quality of life and other important patient-reported outcomes such as fatigue and weight gain. This study does, however, provide helpful information that desiccated thyroid products are a reasonable choice for treating some hypothyroid patients. Keeping desiccated thyroid medications as an option in our tool kit will allow for improved shared decision making, while allowing for patient preference, and offer an option for those patients who remain symptomatic on levothyroxine monotherapy.

Footnotes

  • Conflicts of interest: authors report none.

  • To read or post commentaries in response to this article, see it online at https://www.AnnFamMed.org/content/18/5/388.

  • Received for publication July 22, 2020.
  • Accepted for publication August 5, 2020.
  • © 2020 Annals of Family Medicine, Inc.

References

  1. ↵
    1. Hepp Z,
    2. Wyne K,
    3. Manthena SR,
    4. Wang S,
    5. Gossain V
    . Adherence to thyroid hormone replacement therapy: a retrospective, claims data-base analysis. Curr Med Res Opin. 2018; 34(9): 1673–1678.
    OpenUrl
  2. ↵
    1. Idrees T,
    2. Palmer S,
    3. Maciel RMB,
    4. Bianco AC
    . Liothyronine and desiccated thyroid extract in the treatment of hypothyroidism. [published online ahead of print May 12, 2020]. Thyroid. doi: 10.1089/thy.2020.0153.
    OpenUrlCrossRef
  3. ↵
    1. Hennessey JV
    . The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine. 2017; 55(1): 6–18.
    OpenUrl
  4. ↵
    1. MacGregor AG
    . Why does anybody use thyroid B.P.? Lancet. 1961; 1(7172): 329–332.
    OpenUrlPubMed
  5. ↵
    1. Saravanan P,
    2. Chau WF,
    3. Roberts N,
    4. Vedhara K,
    5. Greenwood R,
    6. Dayan CM
    . Psychological well-being in patients on ‘adequate’ doses of lthyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002; 57(5): 577–585.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Dew R,
    2. King K,
    3. Okosieme OE,
    4. et al
    . Patients’ attitudes and perceptions towards treatment of hypothyroidism in general practice: an in-depth qualitative interview study. BJGP Open. 2017; 1(2):bjgpopen17X100977.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Nexø MA,
    2. Watt T,
    3. Cleal B,
    4. et al
    . Exploring the experiences of people with hypo- and hyperthyroidism. Qualitative Health Research. 2015; 25(7): 945–953.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Peterson SJ,
    2. McAninch EA,
    3. Bianco AC
    . Is a normal TSH synonymous with “euthyroidism” in levothyroxine monotherapy? J Clin Endocrinol Metab. 2016; 101(12): 4964–4973.
    OpenUrl
  9. ↵
    1. Samuels MH,
    2. Kolobova I,
    3. Smeraglio A,
    4. Peters D,
    5. Purnell JQ,
    6. Schuff KG
    . Effects of levothyroxine replacement or suppressive therapy on energy expenditure and body composition. Thyroid. 2016; 26(3): 347–355.
    OpenUrl
  10. ↵
    1. Gullo D,
    2. Latina A,
    3. Frasca F,
    4. Le Moli R,
    5. Pellegriti G,
    6. Vigneri R
    . Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS One. 2011; 6(8): e22552.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Ito M,
    2. Miyauchi A,
    3. Morita S,
    4. et al
    . TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur J Endocrinol. 2012; 167(3): 373–378.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Kuye R,
    2. Riggs C,
    3. King J,
    4. et al
    . Thyroid stimulating hormone stability in patients prescribed synthetic or desiccated thyroid products: a retrospective study. Ann Fam Med. 2020; 18(5): 452–454.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Annals of Family Medicine: 18 (5)
The Annals of Family Medicine: 18 (5)
Vol. 18, Issue 5
September/October 2020
  • Table of Contents
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
  • In Brief
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Annals of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Returning to a Patient-Centered Approach in the Management of Hypothyroidism
(Your Name) has sent you a message from Annals of Family Medicine
(Your Name) thought you would like to see the Annals of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Returning to a Patient-Centered Approach in the Management of Hypothyroidism
Jill Schneiderhan, Suzanna Zick
The Annals of Family Medicine Sep 2020, 18 (5) 388-389; DOI: 10.1370/afm.2602

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Get Permissions
Share
Returning to a Patient-Centered Approach in the Management of Hypothyroidism
Jill Schneiderhan, Suzanna Zick
The Annals of Family Medicine Sep 2020, 18 (5) 388-389; DOI: 10.1370/afm.2602
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Recruiting, Educating, and Taking Primary Care to Rural Communities
  • An Opportunity to Emphasize Equity, Social Determinants, and Prevention in Primary Care
Show more Editorials

Similar Articles

Keywords

  • hypothyroidism
  • primary health care
  • shared decision making

Content

  • Current Issue
  • Past Issues
  • Past Issues in Brief
  • Multimedia
  • Articles by Type
  • Articles by Subject
  • Multimedia
  • Supplements
  • Online First
  • Calls for Papers

Info for

  • Authors
  • Reviewers
  • Media
  • Job Seekers

Engage

  • E-mail Alerts
  • e-Letters (Comments)
  • RSS
  • Journal Club
  • Submit a Manuscript
  • Subscribe
  • Family Medicine Careers

About

  • About Us
  • Editorial Board & Staff
  • Sponsoring Organizations
  • Copyrights & Permissions
  • Contact Us
  • eLetter/Comments Policy

© 2023 Annals of Family Medicine